加载中
NASDAQHealthcareBiotechnology
最新数据
US$545
+US$3.38 · +0.62%
United Therapeutics Corporation, a biotechnology firm, is dedicated to discovering, developing, and bringing to market medical solutions for individuals suffering from chronic and severe, often life-threatening, illnesses. Its operations span both the United States and international markets. The company's current commercial portfolio features several key therapeutics: Remodulin, prescribed for pulmonary arterial hypertension (PAH) to lessen symptoms experienced during physical activity. Tyvaso, an inhaled form of the prostacyclin analogue treprostinil, designed to enhance exercise capacity in patients with PAH and pulmonary hypertension linked to interstitial lung disease (PH-ILD). Orenitram, a treprostinil tablet formulation, also aims to boost the exercise capabilities of PAH patients. Unituxin, a monoclonal antibody utilized in the treatment of high-risk neuroblastoma. Adcirca, an oral PDE-5 inhibitor, which helps improve exercise performance in those with PAH. United Therapeutics also maintains a robust development pipeline, including: Tyvaso DPI, a dry powder inhaler version of Tyvaso. The Remunity Pump, a compact, lightweight, and durable infusion system for treprostinil, accompanied by a separate controller. RemoPro and Ralinepag, both investigational treatments for PAH. Aurora-GT, a gene therapy product focused on regenerating blood vessels within the lungs. Clinical trials such as Tyvaso PERFECT and TETON, which are evaluating Tyvaso's efficacy in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). The company has forged strategic alliances and licensing agreements with various entities, such as DEKA Research & Development Corp. for a semi-disposable subcutaneous treprostinil delivery system; MannKind Corporation for the development and licensing of treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. for the development of Ralinepag. Established in 1996, United Therapeutics Corporation is headquartered in Silver Spring, Maryland.
前收盘价
US$545
+US$3.38 · +0.62%
盘前
US$546.17
+US$1.17 · +0.21%
10月8日 6:19 ET
盘中时间采用ET。市场数据可能有所延迟。
United Therapeutics Corporation, a biotechnology firm, is dedicated to discovering, developing, and bringing to market medical solutions for individuals suffering from chronic and severe, often life-threatening, illnesses. Its operations span both the United States and international markets. The company's current commercial portfolio features several key therapeutics: Remodulin, prescribed for pulmonary arterial hypertension (PAH) to lessen symptoms experienced during physical activity. Tyvaso, an inhaled form of the prostacyclin analogue treprostinil, designed to enhance exercise capacity in patients with PAH and pulmonary hypertension linked to interstitial lung disease (PH-ILD). Orenitram, a treprostinil tablet formulation, also aims to boost the exercise capabilities of PAH patients. Unituxin, a monoclonal antibody utilized in the treatment of high-risk neuroblastoma. Adcirca, an oral PDE-5 inhibitor, which helps improve exercise performance in those with PAH. United Therapeutics also maintains a robust development pipeline, including: Tyvaso DPI, a dry powder inhaler version of Tyvaso. The Remunity Pump, a compact, lightweight, and durable infusion system for treprostinil, accompanied by a separate controller. RemoPro and Ralinepag, both investigational treatments for PAH. Aurora-GT, a gene therapy product focused on regenerating blood vessels within the lungs. Clinical trials such as Tyvaso PERFECT and TETON, which are evaluating Tyvaso's efficacy in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). The company has forged strategic alliances and licensing agreements with various entities, such as DEKA Research & Development Corp. for a semi-disposable subcutaneous treprostinil delivery system; MannKind Corporation for the development and licensing of treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. for the development of Ralinepag. Established in 1996, United Therapeutics Corporation is headquartered in Silver Spring, Maryland.
日内区间
当前US$545
52周区间
当前US$545
盘中时间采用ET。市场数据可能有所延迟。
United Therapeutics Corporation, a biotechnology firm, is dedicated to discovering, developing, and bringing to market medical solutions for individuals suffering from chronic and severe, often life-threatening, illnesses. Its operations span both the United States and international markets. The company's current commercial portfolio features several key therapeutics: Remodulin, prescribed for pulmonary arterial hypertension (PAH) to lessen symptoms experienced during physical activity. Tyvaso, an inhaled form of the prostacyclin analogue treprostinil, designed to enhance exercise capacity in patients with PAH and pulmonary hypertension linked to interstitial lung disease (PH-ILD). Orenitram, a treprostinil tablet formulation, also aims to boost the exercise capabilities of PAH patients. Unituxin, a monoclonal antibody utilized in the treatment of high-risk neuroblastoma. Adcirca, an oral PDE-5 inhibitor, which helps improve exercise performance in those with PAH. United Therapeutics also maintains a robust development pipeline, including: Tyvaso DPI, a dry powder inhaler version of Tyvaso. The Remunity Pump, a compact, lightweight, and durable infusion system for treprostinil, accompanied by a separate controller. RemoPro and Ralinepag, both investigational treatments for PAH. Aurora-GT, a gene therapy product focused on regenerating blood vessels within the lungs. Clinical trials such as Tyvaso PERFECT and TETON, which are evaluating Tyvaso's efficacy in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). The company has forged strategic alliances and licensing agreements with various entities, such as DEKA Research & Development Corp. for a semi-disposable subcutaneous treprostinil delivery system; MannKind Corporation for the development and licensing of treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. for the development of Ralinepag. Established in 1996, United Therapeutics Corporation is headquartered in Silver Spring, Maryland.
日内区间
当前US$545
52周区间
当前US$545
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 31.83亿 USD | 28.77亿 USD | 23.28亿 USD | 19.36亿 USD | 16.86亿 USD |
| 销货成本 | 3.84亿 USD | 3.1亿 USD | 2.58亿 USD | 1.47亿 USD | 1.23亿 USD |
| 毛利 | 27.98亿 USD | 25.68亿 USD | 20.7亿 USD | 17.9亿 USD | 15.63亿 USD |
| 研究与开发 | 5.5亿 USD | 4.81亿 USD | 4.08亿 USD | 3.23亿 USD | 5.4亿 USD |
| 销售、一般及管理费用 | 7.31亿 USD | 6.39亿 USD | 4.77亿 USD | 4.87亿 USD | 4.67亿 USD |
| 营业费用 | 12.81亿 USD | 11.91亿 USD | 8.85亿 USD | 8.1亿 USD | 10.07亿 USD |
| 利息收入 | 1.92亿 USD | 1.99亿 USD | 1.63亿 USD | 4520万 USD | 1670万 USD |
| 利息支出 | 1950万 USD | 4290万 USD | 5930万 USD | 3240万 USD | 1860万 USD |
| 折旧和摊销 | 8560万 USD | 7250万 USD | 5320万 USD | 5130万 USD | 4990万 USD |
| 营业利润 | 15.17亿 USD | 13.77亿 USD | 11.85亿 USD | 9.8亿 USD | 5.56亿 USD |
| 净利润 | 13.35亿 USD | 11.95亿 USD | 9.85亿 USD | 7.27亿 USD | 4.76亿 USD |
公司数据更新于 2026年10月8日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$599.8
上涨空间 10.06%| 行动 | 生效日期 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股票拆分 | 2009年9月23日 | 2:1 | — | — |
已生效 2009年9月23日
2:1
报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI6.88亿0.03%2.3万亿 USD0.03%US$381.03-0.40%
Vanguard Morningstar Small-Cap ETFVB4.98亿0.27%1853亿 USD0.03%US$286.98-1.41%
Vanguard Extended Market ETFVXF2.52亿0.26%954亿 USD0.05%US$233.49-1.56%
State Street SPDR S&P MIDCAP 400 ETF TrustMDY1.72亿0.67%259.8亿 USD0.23%US$663.94-1.64%
iShares Biotechnology ETFIBB1.7亿1.63%104.01亿 USD0.44%US$203.34+0.12%
State Street SPDR S&P Biotech ETFXBI1.65亿1.60%100.75亿 USD0.35%US$150.23-0.44%
Invesco S&P MidCap Quality ETFXMHQ1.6亿2.92%54.77亿 USD0.30%US$112.65-1.87%
Vanguard Morningstar Small-Cap Value ETFVBR1.58亿0.23%682亿 USD0.05%US$232.17-1.32%Vanguard Morningstar Total Stock Market ETFVTIVanguard Morningstar Small-Cap ETFVBVanguard Extended Market ETFVXFState Street SPDR S&P MIDCAP 400 ETF TrustMDYiShares Biotechnology ETFIBBState Street SPDR S&P Biotech ETFXBIInvesco S&P MidCap Quality ETFXMHQVanguard Morningstar Small-Cap Value ETFVBRAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
